Clonal evolution of chronic lymphocytic leukemia (CLL) often follows chemotherapy and is associated with adverse outcome, but also occurs in untreated patients, in which case its predictive role is debated. We investigated whether the selection and expansion of CLL clone(s) precede an aggressive disease shift. We found that clonal evolution occurs in all CLL patients, irrespective of the clinical outcome, but is faster during disease progression. In particular, changes in the frequency of nucleotide variants (NVs) in specific CLL-related genes may represent an indicator of poor clinical outcome.

Genetic dynamics in untreated CLL patients with either stable or progressive disease: A longitudinal study / Ramassone A.; D'Argenio A.; Veronese A.; Basti A.; Soliman S.H.A.; Volinia S.; Bassi C.; Pagotto S.; Ferracin M.; Lupini L.; Saccenti E.; Balatti V.; Pepe F.; Rassenti L.Z.; Innocenti I.; Autore F.; Marzetti L.; Mariani-Costantini R.; Kipps T.J.; Negrini M.; Laurenti L.; Visone R.. - In: JOURNAL OF HEMATOLOGY & ONCOLOGY. - ISSN 1756-8722. - ELETTRONICO. - 12:1(2019), pp. 114.1-114.5. [10.1186/s13045-019-0802-x]

Genetic dynamics in untreated CLL patients with either stable or progressive disease: A longitudinal study

Ferracin M.
Formal Analysis
;
2019

Abstract

Clonal evolution of chronic lymphocytic leukemia (CLL) often follows chemotherapy and is associated with adverse outcome, but also occurs in untreated patients, in which case its predictive role is debated. We investigated whether the selection and expansion of CLL clone(s) precede an aggressive disease shift. We found that clonal evolution occurs in all CLL patients, irrespective of the clinical outcome, but is faster during disease progression. In particular, changes in the frequency of nucleotide variants (NVs) in specific CLL-related genes may represent an indicator of poor clinical outcome.
2019
Genetic dynamics in untreated CLL patients with either stable or progressive disease: A longitudinal study / Ramassone A.; D'Argenio A.; Veronese A.; Basti A.; Soliman S.H.A.; Volinia S.; Bassi C.; Pagotto S.; Ferracin M.; Lupini L.; Saccenti E.; Balatti V.; Pepe F.; Rassenti L.Z.; Innocenti I.; Autore F.; Marzetti L.; Mariani-Costantini R.; Kipps T.J.; Negrini M.; Laurenti L.; Visone R.. - In: JOURNAL OF HEMATOLOGY & ONCOLOGY. - ISSN 1756-8722. - ELETTRONICO. - 12:1(2019), pp. 114.1-114.5. [10.1186/s13045-019-0802-x]
Ramassone A.; D'Argenio A.; Veronese A.; Basti A.; Soliman S.H.A.; Volinia S.; Bassi C.; Pagotto S.; Ferracin M.; Lupini L.; Saccenti E.; Balatti V.; Pepe F.; Rassenti L.Z.; Innocenti I.; Autore F.; Marzetti L.; Mariani-Costantini R.; Kipps T.J.; Negrini M.; Laurenti L.; Visone R.
File in questo prodotto:
File Dimensione Formato  
2019_Visone-CLL.pdf

accesso aperto

Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 1.56 MB
Formato Adobe PDF
1.56 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/709046
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 3
social impact